Bracarda S - Search Results

1

Targeting of EGFR tyrosine kinase by ZD1839 ("Iressa") in androgen-responsive prostate cancer in vitro.

Bellezza I, Bracarda S, Caserta C, Minelli A. Bellezza I, et al. Among authors: bracarda s. Mol Genet Metab. 2006 Jun;88(2):114-22. doi: 10.1016/j.ymgme.2005.12.014. Epub 2006 Feb 17. Mol Genet Metab. 2006. PMID: 16487738 Review.

2

Mechanism of 2-chloroadenosine toxicity to PC3 cell line.

Minelli A, Bellezza I, Agostini M, Bracarda S, Culig Z. Minelli A, et al. Among authors: bracarda s. Prostate. 2006 Sep 15;66(13):1425-36. doi: 10.1002/pros.20458. Prostate. 2006. PMID: 16741921

3

2-chloroadenosine modulates PAR-1 and IL-23 expression and enhances docetaxel effects on PC3 cells.

Minelli A, Bellezza I, Tucci A, Conte C, Bracarda S, Culig Z. Minelli A, et al. Among authors: bracarda s. Prostate. 2008 Mar 1;68(4):360-72. doi: 10.1002/pros.20703. Prostate. 2008. PMID: 18189232

4

[The difficult choice: when not to treat. Hormone-refractory metastatic prostate cancer].

Bracarda S, Caserta C, Tonato M. Bracarda S, et al. Suppl Tumori. 2004 Jul-Aug;3(4):S93. Suppl Tumori. 2004. PMID: 15206226 Italian. No abstract available.

5

Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib.

Bracarda S, Caserta C, Sordini L, Rossi M, Hamzay A, Crinò L. Bracarda S, et al. Ann Oncol. 2007 Jun;18 Suppl 6:vi22-5. doi: 10.1093/annonc/mdm219. Ann Oncol. 2007. PMID: 17591826 Free article. Review.

6

Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation.

Bracarda S, Caserta C, Galli L, Carlini P, Pastina I, Sisani M, Scali S, Hamzaj A, Derosa L, Felici A, Rossi M, Altavilla A, Chioni A, De Angelis V. Bracarda S, et al. Future Oncol. 2015 Nov;11(22):3083-90. doi: 10.2217/fon.15.217. Epub 2015 Oct 5. Future Oncol. 2015. PMID: 26437324

7

Targeted Approaches in Metastatic Castration-Resistant Prostate Cancer: Which Data?

Mosillo C, Calandrella ML, Caserta C, Macrini S, Guida A, Sirgiovanni G, Bracarda S. Mosillo C, et al. Among authors: bracarda s. Cancers (Basel). 2022 Aug 29;14(17):4189. doi: 10.3390/cancers14174189. Cancers (Basel). 2022. PMID: 36077726 Free PMC article. Review.

8

"To Cut or Not to Cut", a Biomolecular Approach to Metastasectomy in Metastatic Clear Cell Renal Cell Carcinoma.

Bracarda S, Guida A, Caserta C. Bracarda S, et al. Eur Urol. 2018 Oct;74(4):481-482. doi: 10.1016/j.eururo.2018.06.039. Epub 2018 Jul 17. Eur Urol. 2018. PMID: 30029820 No abstract available.

9

Looking for a Simplified Diagnostic Model to Identify Potentially Lethal Cases of Prostate Cancer at Initial Diagnosis: An ImGO Pilot Study.

Macrini S, Francesconi S, Caprera C, Lancia D, Corsi M, Gunnellini M, Rocchi A, Pireddu A, Marziani F, Mosillo C, Calandrella ML, Caserta C, Giannarelli D, Guida A, Ascani S, Bracarda S. Macrini S, et al. Among authors: bracarda s. Cancers (Basel). 2022 Mar 17;14(6):1542. doi: 10.3390/cancers14061542. Cancers (Basel). 2022. PMID: 35326693 Free PMC article.

10

Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib.

Iacovelli R, Ciccarese C, Maruzzo M, Atzori F, Galli L, Scagliarini S, Massari F, Verzoni E, Cannella A, Maratta MG, Caserta C, Bimbatti D, Deppieri FM, Dessi M, Paolieri F, Riccardi F, Bracarda S, De Giorgi U, Basso U, Tortora G, Procopio G. Iacovelli R, et al. Among authors: bracarda s. Clin Genitourin Cancer. 2022 Oct;20(5):498.e1-498.e9. doi: 10.1016/j.clgc.2022.06.006. Epub 2022 Jun 9. Clin Genitourin Cancer. 2022. PMID: 35768316

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

227 results

Search Page